ProShare Advisors LLC reduced its holdings in shares of CureVac (NASDAQ:CVAC – Get Rating) by 26.4% during the first quarter, HoldingsChannel.com reports. The fund owned 19,377 shares of the company's stock after selling 6,933 shares during the quarter. ProShare Advisors LLC's holdings in CureVac were worth $380,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also bought and sold shares of CVAC. Capital Fund Management S.A. bought a new stake in CureVac during the fourth quarter worth $3,452,000. Eversept Partners LP bought a new stake in CureVac during the fourth quarter worth $2,917,000. Bank of America Corp DE lifted its holdings in CureVac by 246.6% during the fourth quarter. Bank of America Corp DE now owns 72,885 shares of the company's stock worth $2,501,000 after acquiring an additional 51,856 shares during the period. Schroder Investment Management Group bought a new stake in CureVac during the fourth quarter worth $1,413,000. Finally, Fosun International Ltd bought a new stake in shares of CureVac in the fourth quarter valued at $337,000.
Get CureVac alerts:Analysts Set New Price Targets
Separately, JMP Securities restated a "buy" rating and issued a $37.00 target price on shares of CureVac in a research note on Thursday, June 9th.
CureVac Stock Down 3.3 %
Shares of CVAC opened at $9.70 on Monday. The stock's fifty day moving average price is $13.14 and its two-hundred day moving average price is $15.71. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.39 and a current ratio of 3.45. CureVac has a 1 year low of $9.35 and a 1 year high of $71.63.CureVac Profile
(Get Rating)
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza.
See Also
- Get a free copy of the StockNews.com research report on CureVac (CVAC)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
Want to see what other hedge funds are holding CVAC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CureVac (NASDAQ:CVAC – Get Rating).
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.